Interestingly, our results of the p-Erk1/2 protein level in solamargine-treated cervical cancer cells were consistent with those of the former, which prompted us to presume that perhaps solamargine could modulate the Erk signaling pathway in cervical cancer. This evidence concerns the gene MAPK1 and cervical carcinoma.